Previous 10 | Next 10 |
Clene (CLNN +10.2%)and its wholly owned subsidiary Clene Nanomedicine announced a $1M grant award from the Maryland Department of Housing and Community Development (DHCD) to further support the redevelopment of the Clene manufacturing facility in Elkton, MD. Clene Nanomedicine is a ...
Clene Nanomedicine’s Maryland facility is among the projects and activities awarded funding The manufacturing expansion is in preparation for anticipated commercialization SALT LAKE CITY, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its...
Late-breaker oral presentation by Professor Steve Vucic, University of Sydney Medical School and Northcott Chair of Neurology CNM-Au8®demonstrated significantly slowed disease progression, decreased risk of 6-point ALSFRS-R decline, and improved quality of life in early ALS pat...
Late-breaker oral presentation by Professor Steve Vucic, University of Sydney Medical School and Northcott Chair of Neurology CNM-Au8 ® demonstrated significantly slowed disease progression: decreased risk of 6-point ALSFRS-R decline, and improved quality of life in early...
CNM-Au8 has favorable impact on progression of ALS as measured by joint rank comparison of combined survival and ALSFRS-R change – a clinically meaningful endpoint recommended by the FDA CNM-Au8 showed consistent efficacy across limb and bulbar onset participants for AL...
Gainers: Cumberland Pharmaceuticals CPIX +113%. GBS GBS +28%. NuZee (NASDAQ:NUZE) +25%. ImmunoGen IMGN +24%. MEI Pharma MEIP +23%. Vir Biotechnology VIR +16%. Seres Therapeutics (NASDAQ:MCRB) +16%. Molecular MOLN +15%. Clene (NASDAQ:CLNN) +15%. ImmunityBio IBRX...
Registration trial for CNM-Au8®, a gold nanocrystal suspension Topline data anticipated 2H 2022 World’s first ALS platform trial accelerating the path to new ALS therapies SALT LAKE CITY, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLN...
Clene (NASDAQ:CLNN): Q3 GAAP EPS of $0.42. Revenue of $110K (+12.2% Y/Y) Press Release For further details see: Clene EPS reports Q3 results
Recently announced top-line results from RESCUE-ALS Phase 2 trial with CNM-Au8®, a gold nanocrystal suspension VISIONARY-MS blinded interim data show clinically relevant improvements in the modified MS Functional Composite for the study population through 48 weeks of ...
Gainers: Kiniksa Pharmaceuticals (NASDAQ:KNSA) +13%, Ocugen (NASDAQ:OCGN) +13%, Calliditas Therapeutics (NASDAQ:CALT) +11%, Context Therapeutics (NASDAQ:CNTX) +10%, Bone Biologics (OTCPK:BBLG) +7%. Losers: ABVC BioPharma (NASDAQ:ABVC) -32%, Semler ...
News, Short Squeeze, Breakout and More Instantly...
Clene plans to submit a briefing book to the U.S. Food and Drug Administration by July 13 as Part of Overall Process to Support Approval for CNM-Au8(R) for Treatment of ALS Type C interaction is aimed at obtaining FDA feedback on the potential pathway for a new drug application for CNM-Au8 as a...
Latest figures from the World Health Organization show that more than 8.5 million individuals around the globe are living with Parkinson’s disease . This disease is the fastest-growing neurodegenerative disorder globally, with the number of individuals with this illness more than doubli...
A look at the top 10 most actives in the United States Kazia Therapeutics Limited (KZIA) rose 106.5% to $1.38 on volume of 71,739,314 shares Renalytix plc (RNLX) rose 41.4% to $0.4269 on volume of 54,892,134 shares Maxeon Solar Technologies Ltd. (MAXN) fell 7.4% to $0.1951 on volume of 45...